(Q39372385)

English

Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

X F Guo

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

X F Zhu

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

G S Zhong

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

B G Deng

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

27 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Diseases of the Esophagus

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

487-495

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

The HER-2/neu oncogene in tumors of the gastrointestinal tract

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Emerging drugs for esophageal cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

The ErbB receptors and their role in cancer progression.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Untangling the ErbB signalling network

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Targeted therapies for esophageal cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Esophagogastric cancer: targeted agents.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1111/J.1442-2050.2012.01332.X

Identifiers

10.1111/J.1442-2050.2012.01332.X

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39372385&oldid=2042416875"